EPAS1 and ovarian cancer: Moreover, our findings suggest that HIF‐2α may represent an important target for reversing OCSC‐mediated chemoresistance and HIF‐2α inhibitors in combination with conventional chemotherapy are expected to improve therapeutic outcomes in ovarian cancer patients.